Understanding the Persistence of Immune-mediated Chronic Diseases
了解免疫介导的慢性疾病的持续存在
基本信息
- 批准号:7849263
- 负责人:
- 金额:$ 226.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-30 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AntigensAsthmaAutoimmune DiseasesAutoimmunityChronicChronic DiseaseChronic PhaseDiabetes MellitusDiseaseDisease remissionExcisionExposure toFlareGenerationsImmuneImmune System DiseasesImmune responseImmunityIndividualInfectionMediatingModelingMultiple SclerosisOutputPatternPharmaceutical PreparationsResearchStressSymptomsT-LymphocyteTestingTheophyllineTherapeutic InterventionThymus GlandTimeTissuesabstractingantimicrobialbasenovelpathogenprogramspsychologicpublic health relevance
项目摘要
DESCRIPTION (Provided by the applicant)
Abstract: Autoimmunity and asthma are immune-mediated diseases, which can last for the lifetime of an individual, causing financial, physical, psychological and societal burdens. Many of these diseases are characterized by symptomatic periods or flares, followed by a time of remission. Multiple factors, such as stress and infections, are believed to be responsible for this pattern. During these diseases, T cells are persistently stimulated by self or environmental antigens. Like autoimmune diseases, exposure to pathogens, which cause a chronic infection, also results in constant T cell stimulation by persistent antigens. I have recently demonstrated that new, pathogen-specific T cells are constantly produced during the chronic phase of infection, well after the initial infectious burst has resolved. This continued thymic output was required for maintaining the immune response. As common features can pertain to different immunological situations, the hypothesis to be tested in this proposal is whether the generation of T cells specific for tissue and environmental antigens in autoimmunity and asthma during established disease is a factor responsible for perpetuation of tissue damage. This hypothesis will be tested in different models of diabetes, multiple sclerosis and a novel model of asthma. In addition, manipulation of thymic output during these chronic diseases, as well as during chronic infections, will determine whether newly developed T cells can be programmed to dampen atopic or autoimmune diseases or augment anti-microbial immunity. If successful, these studies may offer a novel explanation for the chronicity of certain immunological diseases and provide a new paradigm on which to base therapeutic intervention.
Public Health Relevance: The research proposed here aims to understand how new T cells that are produced over time contribute to flares in symptoms of autoimmune diseases and asthma. This may also help us to understand why these diseases last a lifetime. Manipulation of newly produced T cells through drugs or removal of the thymus may result in a uniform treatment to interfere with multiple diseases and chronic infections.
描述(由申请人提供)
摘要:自身免疫性疾病和哮喘是免疫介导的疾病,可以持续个体的一生,造成经济、身体、心理和社会负担。许多这些疾病的特征是出现症状期或发作期,然后是缓解期。据信,压力和感染等多种因素是造成这种模式的原因。在这些疾病期间,T 细胞持续受到自身或环境抗原的刺激。与自身免疫性疾病一样,接触病原体会导致慢性感染,也会导致持续性抗原持续刺激 T 细胞。我最近证明,在感染的慢性阶段,在最初的感染爆发消退后很久,新的病原体特异性 T 细胞会不断产生。这种持续的胸腺输出是维持免疫反应所必需的。由于共同特征可能涉及不同的免疫学情况,因此本提案要检验的假设是,在已确定的疾病期间,自身免疫和哮喘中产生的对组织和环境抗原具有特异性的 T 细胞是否是导致组织损伤永久存在的一个因素。这一假设将在不同的糖尿病模型、多发性硬化症模型和一种新型哮喘模型中得到检验。此外,在这些慢性疾病以及慢性感染期间对胸腺输出的控制将决定新开发的 T 细胞是否可以被编程来抑制特应性或自身免疫性疾病或增强抗微生物免疫力。如果成功,这些研究可能会为某些免疫疾病的慢性病提供新的解释,并为治疗干预提供新的范例。
公共健康相关性:本文提出的研究旨在了解随着时间的推移产生的新 T 细胞如何导致自身免疫性疾病和哮喘症状的发作。这也可能有助于我们理解为什么这些疾病会持续一生。通过药物或切除胸腺操纵新产生的 T 细胞可能会产生统一的治疗方法,以干扰多种疾病和慢性感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VAIVA D VEZYS其他文献
VAIVA D VEZYS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VAIVA D VEZYS', 18)}}的其他基金
Mechanisms of reduced T cell autoimmunity with immune experience
免疫经验降低T细胞自身免疫的机制
- 批准号:
10632556 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别:
Mechanisms of reduced T cell autoimmunity with immune experience
免疫经验降低T细胞自身免疫的机制
- 批准号:
10632556 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别:
Therapeutic vaccination targeting SIV viral reservoirs
针对 SIV 病毒库的治疗性疫苗接种
- 批准号:
8930062 - 财政年份:2014
- 资助金额:
$ 226.5万 - 项目类别:
Therapeutic vaccination targeting SIV viral reservoirs
针对 SIV 病毒库的治疗性疫苗接种
- 批准号:
8842310 - 财政年份:2014
- 资助金额:
$ 226.5万 - 项目类别:
相似国自然基金
睡眠剥夺通过上调BMAL1/IL-17轴促进三级淋巴结构形成加重哮喘的研究
- 批准号:82300039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于呼吸道菌群失衡介导NLRP3炎症小体激活探讨清肺涤痰治法改善哮喘气道炎症的作用机制
- 批准号:82304934
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ADRA2a调控滤泡辅助性T细胞与生发中心B细胞相互作用参与哮喘发病的机制研究
- 批准号:82370025
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
NmU与PGD2协同调控2型免疫反应促进嗜酸性粒细胞型哮喘进程的机制研究
- 批准号:82300024
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Neuropilin-1活化肺2型固有淋巴样细胞促进肺哮喘发生的机制研究
- 批准号:32300727
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Polymer-derived biomaterials for mRNA delivery to induce antigen-specific immune tolerance
用于 mRNA 递送以诱导抗原特异性免疫耐受的聚合物衍生生物材料
- 批准号:
10886168 - 财政年份:2023
- 资助金额:
$ 226.5万 - 项目类别:
Precision Medicine Description of Novel Asthma Endotype
新型哮喘内型的精准医学描述
- 批准号:
10580870 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别:
Chemotactic Cytokines Gordon Research Conference and Seminar
趋化细胞因子戈登研究会议及研讨会
- 批准号:
10468353 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别:
Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis
开发 ITCH 激活 IRAK4 降解剂作为治疗类风湿性关节炎的双靶点候选药物
- 批准号:
10545911 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别:
The impact of Aryl hydrocarbon receptor signaling on Toll like receptor-mediated inflammation
芳基碳氢化合物受体信号传导对 Toll 样受体介导的炎症的影响
- 批准号:
10569113 - 财政年份:2022
- 资助金额:
$ 226.5万 - 项目类别: